ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK

ETC-1002 is an investigational drug currently in Phase 2 development for treatment of dyslipidemia and other cardiometabolic risk factors. In dyslipidemic subjects, ETC-1002 not only reduces plasma LDL cholesterol but also significantly attenuates levels of hsCRP, a clinical biomarker of inflammatio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Filippov, Sergey, Pinkosky, Stephen L., Lister, Richard J., Pawloski, Catherine, Hanselman, Jeffrey C., Cramer, Clay T., Srivastava, Rai Ajit K., Hurley, Timothy R., Bradshaw, Cheryl D., Spahr, Mark A., Newton, Roger S.
Formato: Artigo
Idioma:Inglês
Publicado em: The American Society for Biochemistry and Molecular Biology 2013
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3708360/
https://ncbi.nlm.nih.gov/pubmed/23709692
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1194/jlr.M035212
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados